Table of Contents
PITTSBURGH — Mylan Inc. has released bromfenac ophthalmic solution 0.09%, which alleviates swelling and pain caused by cataract surgery.
The company said this week that the twice daily administration product, rolled out by its Mylan Pharmaceuticals Inc. subsidiary, was launched through a development and supply agreement with Coastal Pharmaceuticals.
According to Mylan, this product is the first generic version of ISTA’s Xibrom Ophthalmic Solution 0.09%, a treatment for inflammation in patients who have undergone cataract extraction.
Bromfenac ophthalmic solution had U.S. sales of about $116 million for the 12 months ended March 31, based on IMS Health data provided by Mylan.
